Biodesix is a data-driven diagnostic solutions company that provides lung cancer diagnostic testing and biopharma services.
Biodesix is a data-driven diagnostic solutions company that provides lung cancer diagnostic testing and biopharma services. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring, and better therapeutic guidance, which may lead to improved patient outcomes. Biodesix discovers, develops, and commercializes multivariate protein diagnostics based on its proprietary mass spectrometry-based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix’s first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix’s CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve the utility of therapeutic agents.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 17, 2022 | Post-IPO Equity | $40.30M | — | — | — | Detail |
Nov 16, 2022 | Post-IPO Debt | $50M | 1 | Perceptive Advisors | — | Detail |
Apr 7, 2022 | Post-IPO Equity | $11.70M | — | — | — | Detail |
Mar 7, 2022 | Post-IPO Equity | $50M | 1 | Lincoln Park Capital Fund | — | Detail |
Mar 23, 2021 | Post-IPO Debt | $30M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Perceptive Advisors | Yes | Post-IPO Debt |
Lincoln Park Capital Fund | Yes | Post-IPO Equity |
CRG | — | Debt Financing |
Biodesix has acquired 2 organizations. Their most recent acquisition was Integrated Diagnostics on Jul 9, 2018. They acquired Integrated Diagnostics for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Jul 9, 2018
Integrated Diagnostics
|
Biotechnology | acquisition | — | Detail |
Jun 28, 2019
Oncimmune
|
Biotechnology | acquisition | — | Detail |